Nektar Therapeutics (NKTR)
| Market Cap | 1.16B |
| Revenue (ttm) | 62.60M |
| Net Income (ttm) | -120.74M |
| Shares Out | 20.34M |
| EPS (ttm) | -7.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 342,873 |
| Open | 57.99 |
| Previous Close | 57.69 |
| Day's Range | 55.67 - 58.10 |
| 52-Week Range | 6.48 - 66.92 |
| Beta | 1.28 |
| Analysts | Strong Buy |
| Price Target | 106.33 (+86.87%) |
| Earnings Date | Nov 6, 2025 |
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro... [Read more]
Financial Performance
In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $106.33, which is an increase of 86.87% from the latest price.
News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified st...
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets
Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Der...
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout
Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases, with Rezpegaldesleukin (Rezpeg) as its lead asset. NKTR's value now centers on Treg biology, advancing R...
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dos...
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Nektar Therapeutics ( NKTR) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Vivian Wu Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Resea...
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable secu...
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Confere...
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based ...
San Francisco is making a comeback. So are these stocks from the City by the Bay
CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist ...
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
Nektar Therapeutics (NKTR -2.34%) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January.
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Shares of Nektar Therapeutics (NKTR 0.08%), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly enthusias...
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today
Clinical-stage biotech Nektar Therapeutics (NKTR 15.06%) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances...
Why Is Nektar Therapeutics Stock Trading Lower On Thursday?
Nektar Therapeutics Inc. NKTR on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 202...
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis High dose rezpegaldesleukin achieved statistical significance on multiple patient-reporte...
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of...
Why Nektar Therapeutics Rippled Higher This Week
Nektar Therapeutics (NKTR 7.73%) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program.
What's Going On With Nektar Therapeutics Stock On Thursday?
Nektar Therapeutics Inc. NKTR stock traded higher on Thursday, with a session volume of 2.80 million versus the average volume of 1.96 million, according to data from Benzinga Pro.
Nektar Therapeutics to Participate in Two Investor Conferences in September
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief R...
Why Nektar Therapeutics Stock Popped 6% on Friday
Biotech Nektar Therapeutics (NKTR 6.02%) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, ...
Nektar (NKTR) Q2 Revenue Falls 52%
Nektar (NKTR) Q2 Revenue Falls 52%
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
SAN FRANCISCO , Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable securiti...
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based f...